Kobayashi Pharmaceutical was reported to be considering going private, prompting a sharp reaction in the form of buy orders. This article organizes the mechanisms of TOBs, MBOs and squeeze-outs, along with steps retail investors can take to avoid losses, limiting the discussion to the facts presented in the article.
On 24 September 2026, Kobayashi Pharmaceutical was reported to be considering taking its shares private, and a rush of buy orders sent the stock to a limit-up buy indication in the market on the following day, the 25th. Multiple reports were cited as the source of the news, and a view spread that consideration was progressing toward accepting the proposal. Kobayashi Pharmaceutical is a well-known company whose brands include Nodo Nuru and Netsusama Sheet, and it had many individual shareholders.
The current case could constitute an acquisition-driven delisting. Against the backdrop of an era in which TOBs and MBOs are becoming more common, the article discusses the mechanics of going private and the issues involved in ensuring fairness. The purchase price and any formal decision have not been disclosed, but attention is focused on the process by which shareholders receive cash as the acquirer acquires the shares and on whether a premium is offered.
The basic terms of a TOB are the tender period, offer price, minimum and maximum tender conditions. When delisting is intended, the minimum tender condition is often set as a percentage of voting rights. A squeeze-out is the typical second-stage procedure for forcibly acquiring shares from shareholders who did not tender, using mechanisms such as a share consolidation or a demand for the sale of shares, etc.
Options for individual investors include checking information at the reporting stage and the formal announcement stage, reviewing the 7 key checkpoints after the TOB is announced, and comparing 3 choices: selling, tendering the shares or continuing to hold them. Attention is also required regarding the treatment of NISA accounts, tax considerations, dividends and shareholder benefits. The possibility of filing a petition to determine the price is also noted.